TransCode Therapeutics (RNAZ) Competitors $0.41 -0.03 (-5.88%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$0.49 +0.08 (+20.51%) As of 09:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAZ vs. GBIO, VYNE, DARE, CLNN, TPST, GDTC, QTTB, LEXX, CARA, and CYTHShould you be buying TransCode Therapeutics stock or one of its competitors? The main competitors of TransCode Therapeutics include Generation Bio (GBIO), VYNE Therapeutics (VYNE), Daré Bioscience (DARE), Clene (CLNN), Tempest Therapeutics (TPST), CytoMed Therapeutics (GDTC), Q32 Bio (QTTB), Lexaria Bioscience (LEXX), Cara Therapeutics (CARA), and Cyclo Therapeutics (CYTH). These companies are all part of the "pharmaceutical products" industry. TransCode Therapeutics vs. Generation Bio VYNE Therapeutics Daré Bioscience Clene Tempest Therapeutics CytoMed Therapeutics Q32 Bio Lexaria Bioscience Cara Therapeutics Cyclo Therapeutics TransCode Therapeutics (NASDAQ:RNAZ) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, community ranking, dividends, institutional ownership, risk and earnings. Does the MarketBeat Community prefer RNAZ or GBIO? Generation Bio received 31 more outperform votes than TransCode Therapeutics when rated by MarketBeat users. However, 94.12% of users gave TransCode Therapeutics an outperform vote while only 72.31% of users gave Generation Bio an outperform vote. CompanyUnderperformOutperformTransCode TherapeuticsOutperform Votes1694.12% Underperform Votes15.88%Generation BioOutperform Votes4772.31% Underperform Votes1827.69% Is RNAZ or GBIO more profitable? TransCode Therapeutics has a net margin of 0.00% compared to Generation Bio's net margin of -782.86%. Generation Bio's return on equity of -104.85% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TransCode TherapeuticsN/A -649.03% -281.34% Generation Bio -782.86%-104.85%-49.54% Which has more risk & volatility, RNAZ or GBIO? TransCode Therapeutics has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.78, suggesting that its stock price is 178% more volatile than the S&P 500. Do analysts rate RNAZ or GBIO? TransCode Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 2,359.42%. Generation Bio has a consensus target price of $7.33, suggesting a potential upside of 1,593.22%. Given TransCode Therapeutics' higher probable upside, equities research analysts plainly believe TransCode Therapeutics is more favorable than Generation Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Generation Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, RNAZ or GBIO? TransCode Therapeutics has higher earnings, but lower revenue than Generation Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTransCode TherapeuticsN/AN/A-$18.55MN/AN/AGeneration Bio$19.89M1.46-$126.61M-$1.98-0.22 Does the media refer more to RNAZ or GBIO? In the previous week, TransCode Therapeutics had 2 more articles in the media than Generation Bio. MarketBeat recorded 3 mentions for TransCode Therapeutics and 1 mentions for Generation Bio. Generation Bio's average media sentiment score of 1.89 beat TransCode Therapeutics' score of 1.44 indicating that Generation Bio is being referred to more favorably in the news media. Company Overall Sentiment TransCode Therapeutics Positive Generation Bio Very Positive Do insiders and institutionals have more ownership in RNAZ or GBIO? 95.2% of Generation Bio shares are held by institutional investors. 0.1% of TransCode Therapeutics shares are held by insiders. Comparatively, 21.1% of Generation Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryGeneration Bio beats TransCode Therapeutics on 9 of the 14 factors compared between the two stocks. Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAZ vs. The Competition Export to ExcelMetricTransCode TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.08M$6.89B$5.56B$7.82BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.4422.5718.48Price / SalesN/A242.70395.64103.60Price / CashN/A65.8538.1834.62Price / Book0.006.516.774.25Net Income-$18.55M$143.21M$3.22B$248.23M7 Day Performance1.65%1.97%1.46%0.89%1 Month Performance-24.83%6.89%3.98%3.53%1 Year Performance-99.94%-2.52%16.14%5.09% TransCode Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAZTransCode Therapeutics3.0966 of 5 stars$0.41-5.9%$10.00+2,359.4%-99.9%$10.08MN/A0.009Short Interest ↓Positive NewsGBIOGeneration Bio3.5867 of 5 stars$0.42+6.4%$7.33+1,658.6%-84.7%$27.94M$19.89M-0.19150Positive NewsHigh Trading VolumeVYNEVYNE Therapeutics2.4763 of 5 stars$1.79-3.2%$6.88+284.1%-47.2%$27.23M$501,000.00-2.0830Upcoming EarningsShort Interest ↑DAREDaré Bioscience2.2926 of 5 stars$2.97+2.4%$24.00+708.1%-20.1%$26.28M$9,784.00-5.0330Short Interest ↓CLNNClene2.8313 of 5 stars$3.02+0.7%$55.25+1,729.5%-65.6%$25.96M$342,000.00-0.57100Upcoming EarningsTPSTTempest Therapeutics2.0125 of 5 stars$7.11-2.3%$30.00+321.9%-84.2%$25.02MN/A-4.6520Upcoming EarningsGDTCCytoMed Therapeutics2.1502 of 5 stars$2.28-7.3%$5.00+119.3%+12.3%$24.94MN/A0.00N/AGap DownQTTBQ32 Bio2.6728 of 5 stars$2.03-4.2%$24.71+1,117.5%-94.2%$24.76M$-6,651,000.00-0.1439Upcoming EarningsShort Interest ↓News CoverageGap DownLEXXLexaria Bioscience2.426 of 5 stars$1.39+0.7%$7.00+403.6%-62.5%$24.41M$525,923.00-2.787Short Interest ↓Analyst RevisionCARACara Therapeutics3.8651 of 5 starsN/A$83.52+∞N/A$24.33M$7.14M-0.2580Analyst ForecastPositive NewsGap DownHigh Trading VolumeCYTHCyclo Therapeutics1.3691 of 5 stars$0.72flat$0.95+31.8%N/A$23.72M$870,725.00-0.809 Related Companies and Tools Related Companies Generation Bio Competitors VYNE Therapeutics Competitors Daré Bioscience Competitors Clene Competitors Tempest Therapeutics Competitors CytoMed Therapeutics Competitors Q32 Bio Competitors Lexaria Bioscience Competitors Cara Therapeutics Competitors Cyclo Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAZ) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RNAZ Stock Free RNAZ Stock Alerts